Palisade Bio, Inc. (PALI)
Palisade Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Denver, CA, US. The stock last traded at $1.45, down 7.64% on the session, giving a market capitalisation of $251.7M. On trailing twelve-month figures it carries a trailing P/E of -2.73, a net margin of -6388.2%. Its beta of 1.55 implies it has historically moved more than the broad market.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Palisade Bio, Inc. is most often compared with the following Healthcare names: